Search hospitals > Kentucky > Louisville
Norton Cancer Institute
Claim this profileLouisville, Kentucky 40202
Global Leader in Lymphoma
Global Leader in Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Leukemia
220 reported clinical trials
13 medical researchers
Summary
Norton Cancer Institute is a medical facility located in Louisville, Kentucky. This center is recognized for care of Lymphoma, Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Leukemia and other specialties. Norton Cancer Institute is involved with conducting 220 clinical trials across 170 conditions. There are 13 research doctors associated with this hospital, such as John Hamm, MD, Don Stevens, MD, Jaspreet Grewal, MD, and Joseph Maly.Area of expertise
1Lymphoma
Global LeaderMYC positive
BCL2 positive
BCL6 positive
2Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
Top PIs
John Hamm, MDNorton Cancer Institute1 year of reported clinical research
Expert in Non-Small Cell Lung Cancer
Studies Cancer
24 reported clinical trials
44 drugs studied
Don Stevens, MDNorton Cancer Institute2 years of reported clinical research
Expert in Lymphoma
Studies Non-Hodgkin's Lymphoma
25 reported clinical trials
45 drugs studied
Jaspreet Grewal, MDNorton Cancer Institute3 years of reported clinical research
Studies Head and Neck Cancers
Studies Squamous Cell Carcinoma
9 reported clinical trials
14 drugs studied
Joseph MalyNorton Cancer Institute3 years of reported clinical research
Studies Lymphoma
Studies Leukemia
9 reported clinical trials
19 drugs studied
Clinical Trials running at Norton Cancer Institute
Non-Hodgkin's Lymphoma
Lymphoma
Squamous Cell Carcinoma
B-Cell Lymphoma
Cancer
Non-Small Cell Lung Cancer
Colorectal Cancer
Tumors
Multiple Myeloma
Peripheral T-Cell Lymphoma
1A46 Injection
for Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia
This trial tests a new treatment called 1A46 for adults with advanced blood cancers that haven't responded to other treatments. The treatment works by targeting proteins on cancer cells, helping the immune system destroy them.
Recruiting1 award Phase 1 & 2
REGN5837 + Odronextamab
for Aggressive B-Cell Lymphoma
The study is researching an experimental drug called REGN5837 in combination with another experimental drug, odronextamab. The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose for phase 2 for the combination. The study is focused on patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (B-NHLs). The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in your blood at different times * Whether the body makes antibodies against the study drugs (that could make the drugs less effective or could lead to side effects) * To find out how well the study drugs work against relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (B-NHLs)
Recruiting1 award Phase 1
Nanatinostat + Valganciclovir
for EBV-Positive Lymphoma
This trial tests a combination of nanatinostat and valganciclovir in patients with relapsed or refractory EBV-positive lymphomas. Nanatinostat helps the virus produce proteins that activate valganciclovir to kill cancer cells. The goal is to improve outcomes for these patients. Nanatinostat has shown promise in making EBV-positive lymphoma cells more responsive to antiviral agents.
Recruiting1 award Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Norton Cancer Institute?
Norton Cancer Institute is a medical facility located in Louisville, Kentucky. This center is recognized for care of Lymphoma, Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Leukemia and other specialties. Norton Cancer Institute is involved with conducting 220 clinical trials across 170 conditions. There are 13 research doctors associated with this hospital, such as John Hamm, MD, Don Stevens, MD, Jaspreet Grewal, MD, and Joseph Maly.